- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Idiopathic multicentric Castleman’s disease (iMCD)
- Meeting Date: November 2021
- Public Summary Document (PSD) November 2021 PBAC Meeting - (PDF 1094KB)
- Public Summary Document (PSD) November 2021 PBAC Meeting - (Word 77KB)
Siltuximab – November 2021
Siltuximab: Powder for injection 100 mg, Powder for injection 400 mg; Sylvant®
Last updated
4 March 2022